Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

After chemotherapy failure, if the cancer is also resistant to endocrine therapy, patients face a double obstacle: few ...

and AZ/Daiichi Sankyo's Enhertu (trastuzumab deruxtecan). That is down to the company's ADC technology platform, which means that the cytotoxic payload that circulates systemically after ...

In 2019 the FDA approved Enhertu (fam-trastuzumab-deruxtecan-nxki) to treat adults with certain types of HER2-positive breast cancer. In 2022, the FDA expanded the use of Enhertu to treat ...

New research shows that ENHERTU (trastuzumab deruxtecan) could change the standard of care treatment for metastatic HER2 positive breast cancer patients. The trial compared ENHERTU and Kadcyla, the ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed ...

Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a case ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...

Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will ...